sub:assertion { d:DB05014v:identifier "DB05014" ; v:namespace "drugbank" ; v:uri "http://bio2rdf.org/drugbank:DB05014" ; v:x-identifiers.org <http://identifiers.org/drugbank/DB05014> ; dv:drugbank-id "DB05014" ; dv:x-cas <http://bio2rdf.org/cas:921206-68-0> ; dct:description "XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. XL999 also inhibits FLT4 and SRC. XL999 has the potential to prevent tumor growth â both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of the host angiogenic response. XL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models."@en ; dct:identifier "drugbank:DB05014" ; dct:title "XL999"@en ; adv:Drug ; rdfs:label "XL999 [drugbank:DB05014]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05014> . }